|
1
|
Farrakhova D, Maklygina Y, Romanishkin I, Yakovlev D, Plyutinskaya A, Bezdetnaya L, Loschenov V. Fluorescence imaging analysis of distribution of indocyanine green in molecular and nanoform in tumor model. Photodiagnosis Photodyn Ther 2021; 37:102636. [PMID: 34808398 DOI: 10.1016/j.pdpdt.2021.102636] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2021] [Revised: 11/11/2021] [Accepted: 11/15/2021] [Indexed: 12/13/2022]
Abstract
BACKGROUND The efficient intraoperative identification of tumors requires the development of highly specific near-infrared (NIR) probes as contrast agents. One of the most effective dyes existing in clinic oncology is Indocyanine Green (ICG). However, ICG has a rapid excretion, thus ruling out its extended accumulation in pathological tissues therefore limiting its clinical applications. ICG colloid solution (ICG NPs) consists predominantly of J-aggregates and to a lesser extent of H-aggregates and monomers. In the present study we assessed the spectral properties of ICG nanoforms in preclinical models. METHODS We used optical spectroscopy and video fluorescence navigation to monitor accumulation and distribution of ICG monomers and ICG NPs in various tissues in mice with xenografted laryngopharyngeal carcinoma after intravenous drugs injection. RESULTS After i.v. injection, the molecular form of ICG was not retained in the tumor and its circulation cycle averaged 5 min. Alternatively, the nanoform of the drug had a different pharmacokinetics, reaching maximum accumulation 24 h after intravenous injection. Moreover, once in the circulation, we observed a progressive accumulation in the tumor of both ICG H-aggregates and ICG monomers, but not J-aggregates. CONCLUSION Spectral characteristics of ICG NPs indicated the presence of several fractions, namely, J- and H-aggregates along with molecular forms. These fractions had different fluorescence spectra, allowing us to track the transformation of the drug in vivo conditions. After ICG NPs administration, J-aggregates induce accumulation of monomeric forms in the tumor, enabling extended intraoperative diagnostic, and as such further studies of J-aggregates for theranostic applications in oncological surgery are of great interest.
Collapse
Affiliation(s)
- Dina Farrakhova
- Prokhorov General Physics Institute of the Russian Academy of Science, Vavilova str.38, Moscow 119991, Russia.
| | - Yulia Maklygina
- Prokhorov General Physics Institute of the Russian Academy of Science, Vavilova str.38, Moscow 119991, Russia
| | - Igor Romanishkin
- Prokhorov General Physics Institute of the Russian Academy of Science, Vavilova str.38, Moscow 119991, Russia
| | - Dmitry Yakovlev
- Prokhorov General Physics Institute of the Russian Academy of Science, Vavilova str.38, Moscow 119991, Russia; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Science, Miklukho-Maklaya str., 16/10, Moscow 117997, Russia
| | - Anna Plyutinskaya
- National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, 2nd Botkin Ave. 3, Moscow 125284, Russia
| | - Lina Bezdetnaya
- Centre de Recherche en Automatique de Nancy, CNRS, Université de Lorraine, Campus Sciences Boulevard des Aiguillettes BP 70239 54506 Vandoeuvre Les Nancy Cedex, Vandoeuvre-lès-Nancy 54519, France; Institut de Cancérologie de Lorraine, 6 Av. de Bourgogne, Vandoeuvre-lès-Nancy 54519, France
| | - Victor Loschenov
- Prokhorov General Physics Institute of the Russian Academy of Science, Vavilova str.38, Moscow 119991, Russia; National Research Nuclear University "MEPhI", Kashirskoe shosse, 31, Moscow 115409, Russia
| |
Collapse
|
|
2
|
Farrakhova D, Shiryaev A, Yakovlev D, Efendiev K, Maklygina Y, Borodkin A, Loschenov M, Bezdetnaya L, Ryabova A, Amirkhanova L, Samoylova S, Rusakov M, Zavodnov V, Levkin V, Reshetov I, Loschenov V. Trials of a Fluorescent Endoscopic Video System for Diagnosis and Treatment of the Head and Neck Cancer. J Clin Med 2019; 8:jcm8122229. [PMID: 31861124 PMCID: PMC6947089 DOI: 10.3390/jcm8122229] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Revised: 12/09/2019] [Accepted: 12/13/2019] [Indexed: 11/30/2022] Open
Abstract
This article presents the results of intraoperative fluorescent diagnostics via the endoscopic system for assessing the quality of photodynamic therapy (PDT) of head and neck cancer. The diagnosis and PDT procedures were performed on the five patients with malignant neoplasms of the vocal cords, lateral surface of the tongue, and trachea and cancer of the left parotid salivary gland. Molecular form of chlorin E6 (Ce6) was intravenously administered with a 1.0–1.1 mg/kg concentration for PDT. Fluorescent diagnostics (FD) was conducted before PDT and after PDT procedures. Control of PDT efficiency was carried out by evaluating the photobleaching of the drug (photosensitizer). The method of intraoperative fluorescent imaging allows determining the exact location of the tumor and its boundaries. The assessment of photosensitizer photobleaching in real time regime allows making quick decisions during PDT procedure, which helps improving the quality of patients’ treatment. The results showed the convenience of endoscopic fluorescent video system in various nosologies of head and neck cancer. Therefore, this diagnostic approach will improve the effectiveness of cancer treatment.
Collapse
Affiliation(s)
- Dina Farrakhova
- Prokhorov General Physics Institute of the Russian Academy of Sciences, 119991 Moscow, Russia; (Y.M.); (A.B.); (M.L.); (A.R.); (V.L.)
- Correspondence: ; Tel.: +7-968-587-52-75
| | - Artem Shiryaev
- University Clinical Hospital no. 1, Oncology Center, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation, 119991 Moscow, Russia; (A.S.); (L.A.); (S.S.); (M.R.); (V.Z.); (V.L.); (I.R.)
| | - Dmitry Yakovlev
- Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997 Saratov, Russia;
| | - Kanamat Efendiev
- Department of Laser Micro-, Nano-, and Biotechnology, Institute of Engineering Physics for Biomedicine, National Research Nuclear University “MEPhI”, 115409 Moscow, Russia;
| | - Yulia Maklygina
- Prokhorov General Physics Institute of the Russian Academy of Sciences, 119991 Moscow, Russia; (Y.M.); (A.B.); (M.L.); (A.R.); (V.L.)
| | - Alexandr Borodkin
- Prokhorov General Physics Institute of the Russian Academy of Sciences, 119991 Moscow, Russia; (Y.M.); (A.B.); (M.L.); (A.R.); (V.L.)
| | - Maxim Loschenov
- Prokhorov General Physics Institute of the Russian Academy of Sciences, 119991 Moscow, Russia; (Y.M.); (A.B.); (M.L.); (A.R.); (V.L.)
| | - Lina Bezdetnaya
- Centre de Recherche en Automatique de Nancy, CNRS, Université de Lorraine, 54519 Vandœuvre-lès-Nancy, France;
- Institut de Cancérologie de Lorraine, 54519 Vandoeuvre-lès-Nancy, France
| | - Anastasia Ryabova
- Prokhorov General Physics Institute of the Russian Academy of Sciences, 119991 Moscow, Russia; (Y.M.); (A.B.); (M.L.); (A.R.); (V.L.)
- Department of Laser Micro-, Nano-, and Biotechnology, Institute of Engineering Physics for Biomedicine, National Research Nuclear University “MEPhI”, 115409 Moscow, Russia;
| | - Liana Amirkhanova
- University Clinical Hospital no. 1, Oncology Center, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation, 119991 Moscow, Russia; (A.S.); (L.A.); (S.S.); (M.R.); (V.Z.); (V.L.); (I.R.)
| | - Svetlana Samoylova
- University Clinical Hospital no. 1, Oncology Center, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation, 119991 Moscow, Russia; (A.S.); (L.A.); (S.S.); (M.R.); (V.Z.); (V.L.); (I.R.)
| | - Mikhail Rusakov
- University Clinical Hospital no. 1, Oncology Center, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation, 119991 Moscow, Russia; (A.S.); (L.A.); (S.S.); (M.R.); (V.Z.); (V.L.); (I.R.)
| | - Victor Zavodnov
- University Clinical Hospital no. 1, Oncology Center, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation, 119991 Moscow, Russia; (A.S.); (L.A.); (S.S.); (M.R.); (V.Z.); (V.L.); (I.R.)
| | - Vladimir Levkin
- University Clinical Hospital no. 1, Oncology Center, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation, 119991 Moscow, Russia; (A.S.); (L.A.); (S.S.); (M.R.); (V.Z.); (V.L.); (I.R.)
| | - Igor Reshetov
- University Clinical Hospital no. 1, Oncology Center, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation, 119991 Moscow, Russia; (A.S.); (L.A.); (S.S.); (M.R.); (V.Z.); (V.L.); (I.R.)
| | - Victor Loschenov
- Prokhorov General Physics Institute of the Russian Academy of Sciences, 119991 Moscow, Russia; (Y.M.); (A.B.); (M.L.); (A.R.); (V.L.)
- Department of Laser Micro-, Nano-, and Biotechnology, Institute of Engineering Physics for Biomedicine, National Research Nuclear University “MEPhI”, 115409 Moscow, Russia;
| |
Collapse
|